Form 4: Puma Biotechnology Director Adrian Senderowicz Boosts Stake with RSU Grant

Puma Biotechnology, Inc. Director Adrian Senderowicz has acquired 27,000 Restricted Stock Units (RSUs), increasing his beneficial ownership to 54,000 shares.

Summary

• Adrian Senderowicz, a Director of Puma Biotechnology, Inc. (PBYI), acquired 27,000 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 11, 2025.
• The acquisition was a grant with a price of $0 per share.
• Following this transaction, Mr. Senderowicz beneficially owns a total of 54,000 shares of Common Stock.
• The RSUs are set to vest in full on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the annual shareholder meeting following the grant date, contingent upon his continued service with the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director increasing their stake, even through a grant, generally signals confidence in the company's future and aligns their interests with shareholders. It's a standard compensation practice.

Positives

• The acquisition of 27,000 Restricted Stock Units by Director Adrian Senderowicz increases his direct stake in Puma Biotechnology, aligning his interests more closely with those of shareholders.
• Grants of RSUs at a $0 price are a common form of equity compensation, indicating continued commitment and incentivization for the director's service.

Future Outlook

The acquired Restricted Stock Units are subject to a vesting schedule, which will occur on the earlier of the one-year anniversary of the grant date (June 11, 2026) or the date of the annual shareholder meeting following the grant date, provided the reporting person continues their service with the Issuer.

Industry Context

This Form 4 filing details a routine insider transaction, specifically an equity grant to a director, which is a common practice in the biotechnology industry to align management and board interests with shareholder value. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• The acquisition of 27,000 Restricted Stock Units by Adrian Senderowicz, a Director of Puma Biotechnology, Inc., constitutes a related party transaction as it involves the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a director through an RSU grant can be viewed positively as it enhances alignment between the director's financial interests and the company's long-term performance, potentially leading to more shareholder-friendly decisions.
• Employees: While not directly impacted, such grants are part of a broader compensation philosophy that can influence overall employee morale and retention if perceived as fair and performance-driven.
• Management: The grant incentivizes the director to contribute to the company's success, as the value of the RSUs is tied to the company's stock performance.

Next Steps

• The Restricted Stock Units will vest on the earlier of June 11, 2026, or the date of the annual shareholder meeting following the grant date, subject to Adrian Senderowicz's continued service with Puma Biotechnology, Inc.

Key Dates

Keywords

Puma Biotechnology, PBYI, Adrian Senderowicz, Restricted Stock Units, RSU grant, insider transaction, SEC Form 4, director compensation, equity compensation, beneficial ownership